Close Menu
HCP Access Only

Press Release: CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

Gerald NgBy
Exclusively for HCP Portal 5 1
Exclusively for HCP Portal 5 1
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK).

Log In or Register as a healthcare professional to read the full article.

Share.
cropped Circle

Gerald Ng is a previous editor for Medical Channel Asia. Writing has always been his first love and he has more than a decade of journalism experience after falling in love with reading the newspapers daily growing up in Singapore. His works and interviews have appeared in various media publications including Yahoo!, Straits Times and Channel NewsAsia.

Related Posts

MCAsia Long Logo white e1725635014416
Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

Register with us by filling out the form below. Or click here to login for existing user.

Address Fields
The address information you provide will be used for verifying your identity and personalizing your experience on our platform. We ensure the confidentiality and security of your address details in compliance with our privacy policy.
Identification
Your identification details are required for secure account creation and to ensure that your profile is unique and verifiable.